FGFR3-TACC3 Fusion Detection in Cervical Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is no reported detection method for the FGFR3-TACC3 fusion protein or fusion gene in female genital cancers, which limits the ability to identify patients eligible for FGFR3 inhibitors.
Innovation Solution
A method for detecting the FGFR3-TACC3 fusion protein or fusion gene in cervical squamous epithelial tissue samples using techniques such as PCR, FISH, and sequencing, allowing for the identification of cancer patients who can be treated with FGFR3 inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If detection methods for FGFR3-TACC3 fusion are applied to female genital cancers, then diagnostic accuracy for targeted therapy eligibility is improved, but previously no detection capability existed for this cancer type
Solution Approach 1:
The patent develops detection methods using PCR, FISH, and sequencing techniques that are universally applicable across multiple cancer types including female genital cancers. The primer sets and probe sets designed can detect FGFR3-TACC3 fusion in various tissues, making the detection system multi-functional rather than cancer-type-specific.
2Reliability
If molecular diagnosis is implemented for cervical cancer, then therapeutic effect stratification is improved, but complexity of diagnostic procedures increases
Solution Approach 1:
The patent divides the diagnostic process into distinct modular components: DNA extraction, PCR amplification with specific primer sets, FISH analysis with designed probe sets, and sequencing. Each module can be performed independently with standardized protocols, reducing overall procedural complexity while maintaining reliable therapeutic effect prediction.
Solution Approach 2:
The patent introduces specific primer sets and probe sets as intermediary tools that bridge the gap between complex molecular analysis and simple diagnostic interpretation. These intermediaries convert complex genetic information into detectable signals that indicate therapeutic response eligibility.
3Productivity
If FGFR3-TACC3 fusion detection is performed in cervical squamous epithelial tissue, then identification of inhibitor-eligible patients is improved, but sample analysis complexity increases
Solution Approach 1:
The patent performs preliminary design and validation of tissue-specific primer sets and probe sets optimized for cervical squamous epithelial tissue. By pre-optimizing these detection tools for the specific tissue type, the actual patient sample analysis becomes simpler and more efficient, as the detection system is already tailored to the target tissue's characteristics.
Data Source
AI summary
A polynucleotide, which is a novel causative gene for cancer, is elucidated, and, based on this finding, provided are a method for detecting the polynucleotide, or a polypeptide encoded by the polynucleotide; a kit and a primer set for the detection; a method for screening an inhibitor of the polypeptide; and a pharmaceutical composition for treating a cancer containing the inhibitor. In the detection method of the present invention, an FGFR3 fusion protein, or a fusion gene encoding the fusion protein, or a TACC3 fusion protein, or a fusion gene encoding the fusion protein, is detected in a sample derived from female genitalia obtained from a subject.